Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Erratum: HLA-DRA Class II Molecule as a Marker for Immuno-Active Tumors and Its Role in Predicting Response to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer

  • By

  • Jie Mei

  • Guanyu Jiang

  • Yundi Chen

  • Yongrui Xu

  • Yuan Wan

  • Ruo Chen

  • Feng Liu

  • Wenjun Mao

  • Mingfeng Zheng

  • Junying Xu

  • September 17, 2026

Share

Objective:

Correction of an error in the original publication regarding the figures presented.

Approach:
  • Error Identification: The authors identified a duplication error in Fig. 5E related to the PR HLA-DRA and PR PD-L1 panels.
  • Correction: A corrected version of Fig. 5E was provided, showing the appropriate image in the PR PD-L1 panel.
Key Findings:
  • The correction does not alter the study’s conclusions.
Interpretation:

The authors confirm the integrity of the study's findings despite the figure error.

Conclusion:

The erratum serves to clarify the figure without impacting the original study conclusions.

Sources:

Original Source(s)

Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

  • by Jie Mei, Guanyu Jiang, Yundi Chen, Yongrui Xu, Yuan Wan, Ruo Chen, Feng Liu, Wenjun Mao, Mingfeng Zheng, Junying Xu

  • September 17, 2026

Related Content

Cost-Effectiveness of Electronic Patient-Reported Outcome Measure Interventions in Cancer: Systematic Review and Parameter Extraction for Economic Modeling

Retraction Note: TWIST1 activates cancer stem cell marker genes to promote epithelial‑mesenchymal transition and tumorigenesis in esophageal squamous cell carcinoma

The evolution of RTOG and NRG Oncology CNS tumors clinical trials